Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women with newly diagnosed DCIS. Women will be considered to be in menopause if they fall into one of the following groups:~  * Age \> 60~ * Age \> 45 with amenorrhea \> 1 year with intact uterus~ * Status post bilateral oophorectomies~ * FSH/estradiol levels in postmenopausal range for the institution~* DCIS must have been diagnosed with a minimally invasive biopsy technique, such as a vacuum-assisted large core tool (Mammotome) or an equivalent method.~* There must be available tissue from the diagnostic biopsy to perform molecular markers.~* Baseline mammogram within 8 weeks of study entry.~* Serum creatinine less than or equal to 2.0 mg/dl.~* Total bilirubin less than or equal to 2.0 upper limit of normal (ULN), transaminases (SGOT and/or SGPT) and alkaline phosphatase may be up to 2.5 x institutional upper limit of normal (ULN), AGC greater than or equal to 1500, platelets greater than or equal to 100,000, Hemoglobin greater than or equal to 8.0 g/dl~* Peripheral neuropathy grade 0-1.~* No prior therapy for DCIS.~* SWOG performance status of less than or equal to 1~* All patients must provide informed written consent~Exclusion Criteria:~* Prior hormonal therapy (antiestrogens, estrogen, SERM's, progestins, or aromatase inhibitors) within 6 months of study entry.~* Underlying medical, psychiatric or social conditions that would preclude patient from receiving treatment.~* History of DVT or Pulmonary Embolism

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): None
- 2 (Type: ACTIVE_COMPARATOR): Tamoxifen 20 mg
- 3 (Type: ACTIVE_COMPARATOR): Fulvestrant 250mg
- 4 (Type: ACTIVE_COMPARATOR): Fulvestrant 500mg IM

Based on this trial design, predict the completion outcome and termination type (if applicable).